Working groups

Click here for the member area of WGIV Artificial Intelligence in Pharmacovigilance

Working Group XIV Artificial Intelligence in Pharmacovigilance

The first meeting held in Geneva in May 2022 was a hybrid of in-person and virtual meeting, only those physically present are seen above.

Background

Since the early 2000s, the ability of computer algorithms to solve pre-specified tasks previously performed by human specialists has rapidly evolved. This falls within a field of research referred to as Artificial Intelligence born in the 1950’s and dedicated to the study of intelligent agents – systems that can perceive their environment, act autonomously to achieve certain goals and adapt their behaviour over time. Intelligence augmentation is the combination of artificial and human intelligence seeking to complement and enhance human specialist performance.

Already, well-resourced regulatory authorities and biopharmaceutical companies are adopting automated or semi-automated approaches to data management and analysis – a digital transformation catalyzed by the unprecedented volumes of incoming individual case reports to process and assess during the COVID-19 vaccination campaigns.

Artificial intelligent agents can free human experts from tedious and repetitive tasks in pharmacovigilance, allowing them to dedicate their time and efforts to analyses requiring the full breadth and depth of their expertise, such as differential diagnosis or causality assessment. Moreover, intelligent agents can distil and compile information from vast and diverse data sources, enabling human specialists to make better-informed decisions and highlight patterns that they may miss.

In contrast, misguided automation efforts focused exclusively on efficiency and financial targets, risk eliminating the value added by humans in the loop and could ultimately compromise the unique strength of the pharmacovigilance system which has been designed to capture data specifically for the purpose of causality assessment in the individual case.

CIOMS Full Concept Note on AI in PV

Working Group objectives

The objectives of this Working Group are to establish and promote principles and guidance for the use of artificial intelligence or intelligence augmentation in the field of pharmacovigilance building on and complementing the broader initiatives underway.

Progress

  • 1st meeting held on 18-19 May 2022 (Geneva)

CIOMS Working Groups usually take 2-4 years to finalize their consensus document and recommendations. Most groups hold two in-person meetings per year, with telework in between. The groups make use of collaborative efforts and capitalize on existing initiatives in order to provide output that is as comprehensive as possible, does not duplicate other efforts and has added value.

CIOMS MEETINGS

Upcoming Meetings

10 - 11 October 2022

Geneva, Switzerland

2nd Meeting for the Working Group on Artificial Intelligence in Pharmacovigilance

14 September 2022

Virtual

8th meeting of the WG XII on Benefit-Risk Balance for Medicinal Products

09 September 2022

Virtual

15th meeting of the Working Group XIII on Real-World Data & Evidence in Regulatory Decision-Making

06 - 07 September 2022

Geneva, Switzerland

3rd Meeting of the WG on Education and Training for Health Professionals

Recent Meetings